Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HY-133 by HyPharm for Staphylococcal Infections: Likelihood of Approval
HY-133 is under clinical development by HyPharm and currently in Phase I for Staphylococcal Infections. According to GlobalData, Phase I...
HY-133 by HyPharm for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections: Likelihood of Approval
HY-133 is under clinical development by HyPharm and currently in Phase I for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections. According to...
HY-133 by HyPharm for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Likelihood of Approval
HY-133 is under clinical development by HyPharm and currently in Phase I for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to...